GHRP-2 (Pralmorelin)

Overview

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings.

Stimulates endogenous growth hormone release through ghrelin receptor activation.

Indirectly increases IGF-1 levels through enhanced GH secretion.

Enhanced muscle protein synthesis through elevated growth hormone and IGF-1 levels.

Mechanism

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings.

Research areas

• GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.
• GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.
• Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings.
• Stimulates endogenous growth hormone release through ghrelin receptor activation.
• Indirectly increases IGF-1 levels through enhanced GH secretion.
• Enhanced muscle protein synthesis through elevated growth hormone and IGF-1 levels.
• Improved lipolysis and body composition through GH-mediated fat oxidation.
• Faster recovery from exercise and improved sleep quality.
• Myoprotective effects in muscle atrophy models through GHS-R1a stimulation.
• Cytoprotective effects observed in cardiac tissue research.

Research notes

• Increased appetite (less than GHRP-6)
• Mild water retention
• Tingling or numbness in extremities
• Tiredness or lethargy after injection
• Mild headache
• Severe or persistent headaches
• Unusual swelling in hands or feet
• Signs of carpal tunnel syndrome
• Allergic reactions
• Active cancer or history of cancer
• Pregnancy or breastfeeding
• Pituitary disorders
• Diabetic retinopathy
• WADA prohibited for competitive athletes

FAQs